- Home
- SLGB vs LSTA Comparison
SLGB vs LSTA Comparison
Compare SLGB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | Hong Kong | United States |
| Employees | 68 | N/A |
| Industry | Integrated Freight & Logistics | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SLGB | LSTA |
|---|---|---|
| Price | $0.65 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 721.1K | 21.4K |
| Earning Date | 05-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.41 | $1.81 |
| 52 Week High | $6.02 | $5.07 |
Technical Indicators
Market Signals| Indicator | SLGB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 44.48 |
| Support Level | $0.60 | $3.10 |
| Resistance Level | $0.68 | $3.41 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 49.40 | 30.51 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC. The company focuses on industrial raw materials line-haul transportation business. The group focuses on developing a road-transport smart logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.